In The News
Cancer Network – Roy S. Herbst, MD, PhD, Examines the Use of Ramucirumab Plus Pembrolizumab in ICI-Resistant Advanced NSCLC
In a nonmatched substudy of the phase 2 Lung-MAP trial (S1800A; NCT03971474), patients with advanced non–small cell lung cancer who have resistance to immunotherapy were
Bloomberg Law – First Woman Tapped by White House to Head Cancer Institute
A woman will lead the National Cancer Institute for the first time in the agency’s 85-year history, under an announcement made official by the White
The Cancer Letter – White House to appoint Monica Bertagnolli as 16th NCI director
The White House announcement Aug. 10 comes nearly three weeks after news of Bertagnolli’s appointment leaked out on Twitter and in the press (The Cancer Letter, July 21,
Statement From Friends of Cancer Research on Monica Bertagnolli’s Nomination as Director of The National Cancer Institute
Friends of Cancer Research (Friends) commends President Joe Biden on nominating Dr. Monica Bertagnolli as the Director of The National Cancer Institute (NCI). As the
Politico – Clinton-era FDA commissioner to lead external review of key agency offices
Jane Henney, a former commissioner of the FDA, has been tapped by the Reagan-Udall Foundation to lead a FDA-requested external review of key agency offices
GenomeWeb – Stakeholders Urge Collaboration to Prove ctDNA as Regulatory Endpoint for Early Cancer Drugs
NEW YORK – The precision oncology community is hoping it could soon see a new landscape of drug trials using circulating tumor DNA as an
The Pew Charitable Trusts – Senate Committee Advances Legislation to Strengthen Oversight of Diagnostic Tests
The Senate Health, Education, Labor, and Pensions Committee in June approved legislation that would fill critical oversight gaps regarding two widely used health products: diagnostic tests and
The Cancer Letter – Flatiron CEO Carolyn Starrett: We’re reimagining the infrastructure of cancer care, and we’re going global
As real-world evidence becomes ever more essential, a cancer health technology company that played a key role in modernizing 21st-century health data is capitalizing on
Bloomberg Law – Incurable Cancer Patients to See Eased Path to Clinical Trials
Patients with incurable cancers should have an easier time getting into clinical trials under new FDA guidance on developing criteria for trial eligibility. The final
Regulatory Focus – FOCR offers path for validating ctDNA as an early endpoint for drug approval
Friends of Cancer Research (FOCR) has issued an evidentiary roadmap for validating circulatory tumor DNA (ctDNA) as an early endpoint for accelerated drug approval in
